CST BLOG

The official blog of Cell Signaling Technology, where we discuss what to expect from your time at the bench, share tips, tricks, and information.

Emma Mason

Emma Mason

Emma Mason began her scientific career developing and running enzyme-and cell-based screening assays for drug discovery programs in companies including Millennium Pharmaceuticals, AstraZeneca, and Cellzome (a GlaxoSmithKline company). After more than a decade in the lab, she moved into technical support and content writing, before setting up Cambridge Technical Content Ltd in 2017. Today, she produces online material covering a diverse range of topics and has contributed to several immunoassay-focused articles for CST.

Recent Posts:

What Makes a Good Antibody for High-Content Imaging?

High-content imaging (HCI) has utility throughout the entire drug discovery pipeline—from screening ...

Inflammasome Therapeutics: How the Inflammasome Pathway is Being Targeted to Treat Chronic Diseases

Despite having essential roles in immune defense and tissue repair, inflammasomes contribute to the ...

How the Inflammasome Drives Disease: Tackling Aberrant Inflammasome Signaling

Non-communicable diseases such as neurodegeneration, metabolic disorders, and autoimmune disease are...

    Recent Posts